Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

John M S Bartlett; Alison Munro; David A Cameron; Jeremy Thomas; Robin Prescott; Chris J Twelves

doi:10.1200/JCO.2007.14.6597

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

John M S Bartlett, Alison Munro, David A Cameron, Jeremy Thomas, Robin Prescott, Chris J Twelves

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.

Original language	English
Pages (from-to)	5027-35
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	26
Issue number	31
DOIs	https://doi.org/10.1200/JCO.2007.14.6597
Publication status	Published - Nov 2008

Keywords

Adult
Aged
Antibiotics, Antineoplastic
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Cyclophosphamide
DNA Topoisomerases, Type II
DNA-Binding Proteins
Disease-Free Survival
Epirubicin
Female
Fluorouracil
Gene Amplification
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Ki-67 Antigen
Methotrexate
Middle Aged
Patient Selection
Receptor Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Receptor, erbB-2
Receptor, erbB-3
Survival Analysis
Time Factors
Tissue Array Analysis
Treatment Outcome
Tumor Markers, Biological

Access to Document

10.1200/JCO.2007.14.6597

Cite this

@article{45a922490364476cb6b3ea2b685b1843,

title = "Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial",

abstract = "Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.",

keywords = "Adult, Aged, Antibiotics, Antineoplastic, Antigens, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, DNA Topoisomerases, Type II, DNA-Binding Proteins, Disease-Free Survival, Epirubicin, Female, Fluorouracil, Gene Amplification, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Ki-67 Antigen, Methotrexate, Middle Aged, Patient Selection, Receptor Protein-Tyrosine Kinases, Receptor, Epidermal Growth Factor, Receptor, erbB-2, Receptor, erbB-3, Survival Analysis, Time Factors, Tissue Array Analysis, Treatment Outcome, Tumor Markers, Biological",

author = "Bartlett, {John M S} and Alison Munro and Cameron, {David A} and Jeremy Thomas and Robin Prescott and Twelves, {Chris J}",

year = "2008",

month = nov,

doi = "10.1200/JCO.2007.14.6597",

language = "English",

volume = "26",

pages = "5027--35",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "31",

}

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. / Bartlett, John M S ; Munro, Alison ; Cameron, David A; Thomas, Jeremy; Prescott, Robin; Twelves, Chris J.

In: Journal of Clinical Oncology, Vol. 26, No. 31, 11.2008, p. 5027-35.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

AU - Bartlett, John M S

AU - Munro, Alison

AU - Cameron, David A

AU - Thomas, Jeremy

AU - Prescott, Robin

AU - Twelves, Chris J

PY - 2008/11

Y1 - 2008/11

N2 - Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.

AB - Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.

KW - Adult

KW - Aged

KW - Antibiotics, Antineoplastic

KW - Antigens, Neoplasm

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Cyclophosphamide

KW - DNA Topoisomerases, Type II

KW - DNA-Binding Proteins

KW - Disease-Free Survival

KW - Epirubicin

KW - Female

KW - Fluorouracil

KW - Gene Amplification

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Ki-67 Antigen

KW - Methotrexate

KW - Middle Aged

KW - Patient Selection

KW - Receptor Protein-Tyrosine Kinases

KW - Receptor, Epidermal Growth Factor

KW - Receptor, erbB-2

KW - Receptor, erbB-3

KW - Survival Analysis

KW - Time Factors

KW - Tissue Array Analysis

KW - Treatment Outcome

KW - Tumor Markers, Biological

UR - http://www.scopus.com/inward/record.url?scp=54849441046&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.14.6597

DO - 10.1200/JCO.2007.14.6597

M3 - Article

C2 - 18768436

VL - 26

SP - 5027

EP - 5035

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this